The SOUL cardiovascular outcomes trial (CVOT) demonstrated a 14% relative reduction in risk of MACE in patients treated with Rybelsus 14 mg orally once daily for approximately 5 years compared to those who received placebo
The recommendation is to use additional contraceptive methods (or switch to non-oral contraception) during GLP-1 therapy, especially during dose changes
are strictly performing the standard in production and quality control
For the primary endpoint of HbA1c reduction, the mean changes from baseline were -1.87%, -1.89%, and -2.07% for the 5 mg, 10 mg, and 15 mg doses, respectively, compared to a +0.04% change for placebo
That's why the new changes people are reporting while taking certain GLP-1 medications have become so concerning
Intralesional vitamin D3 injection in the treatment of recalcitrant warts: a novel proposition